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ABSTRACT 
B-amyloid is the primary protein component of neuritic plaques, which are 
degenerative foci in brains of patients with Alzheimer's disease (AD). The effects of this 
naturally occurring B-amyloid on the cells of the central nervous system have not been 
completely understood. The effect of cytokines such as IL-IB, TNF-a, and IFN-y on 
astrocytic nitric oxide is well documented; however, the effects of fi-amyloid on astrocytes 
for their cytokine-mediated release of nitric oxide are not established. In the present study 
astrocytic release of nitric oxide was studied following exposure to B-amyloid peptide 
(625-35) in combinations with IL-IB, TNF-a or IFN-y. None of the cytokines induced an 
increase in nitrite levels (nmol/mg protein) in astrocytic cultures by themselves. However, 
IFN-y combined with IL-IB or TNF-a induced a significant increase in nitrite levels. 
Although both IL-IB and TNF-a were effective costimulatory factors, the combination of 
IFN-y and IL-IB was more effective in increasing nitrite levels in cultures than the 
combination of IFN-y and TNF-a. B25-35 completely blocked the increase in nitrite levels by 
IFN-y and TNF-a, whereas B25-35 partially blocked the effect of IFN-7 and IL-IB. These 
findings warrant a further study to determine how the modulatory action of B-amyloid on 
cytokine-mediated astrocytic release of nitric oxide affects neuronal functions in AD 
patients. B-amyloid increases the vulnerability of cultured neurons to 
glutamate-induced excitotoxic damage. Because astrocytes play a key role in uptake of 
extracellular glutamate and glutamate uptake is ATP dependent, we studied the effect of 
B25-35 on glutamate and glucose uptake in cultured hippocampal astrocytes following 7 days 
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of exposure to B25-35. Glutamate uptake by control astrocytes was time-dependent 
Astrocytes exposed to B25-35, however, showed significantly lower glutamate uptake at all 
sampling times. Similarly, ["Cjglucose uptake by astrocytes was inhibited by B25-35. When 
glucose uptake was blocked by phloretin (10 mM), astrocytic pHJglutamate uptake was also 
blocked, suggesting that the inhibitory effect of B-amyloid on glutamate uptake is caused by 
diminished glucose uptake. Thus, our present study suggests a possible link among three 
proposed mechanisms of Alzheimer's disease: astrocytic nitric oxide release, global defect in 
cerebral energy metabolism and glutamate neurotoxicity. 
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GENERAL INTRODUCTION 
Alzheimer's disease (AD) is a neurodegenerative disease affecting 2% to 4% of the 
American population over 65 years of age (American Psychiatric Association, 1997). The 
prevalence of Alzheimer's disease is slightly greater in females than in males, and it is more 
common in individuals with Down's syndrome or a history of head trauma (American 
Psychiatric Association, 1997). Although the majority of Alzheimer's disease cases are 
sporadic, a small portion of patients shows a familial pattern of disease (Talbot et al., 1993). 
Linkage studies have demonstrated that the familial pattern of AD appears in early onset 
cases and is linked to the markers on chromosomes 21,14 and 19. Additionally, they seem 
to be an autosomal dominant trait with full penetrance (Goate et al., 1990; American 
Psychiatric Association, 1997). The existence of a genetic component in late onset AD cases 
has not been confirmed, but is a possibility (Roses et al., 1990; Goate et aL, 1990). 
There are two subtypes of Alzheimer's disease determined by the age of onset 
(American Psychiatric Association, 1997). In Early Onset AD, symptoms of the disease 
begin before 65 years of age while in Late Onset AD they start after the age of 65. Late 
Onset AD is much more common than Early Onset. The course of Alzheimer's disease is 
characterized by an insidious beginning and progressive nature. Early deficits in memory 
are followed by other cognitive disturbances and personality changes, as well as loss of 
judgment and spatial orientation (American Psychiatric Association, 1997). 
Clinical Si^s of Alzheimer's Disease 
The onset of dementia is an essential clinical feature of Alzheimer's disease and also 
a requirement for the diagnosis of the disease. Dementia is a syndrome characterized by 
progressive mental deterioration resulting from multiple cognitive deficits. The cognitive 
deficit must be severe enough to cause an inability of the patient to carry out occupational or 
social activities, and it has to represent a decline in the level of fiinctioning from a previous 
existing level (American Psychiatric Association, 1997; Terry and Katzman, 1983). 
Memory impairment as a component of dementia affects both short-term and long-term 
memory. Individuals suffering from dementia not only forget previously learned material, 
but also have significantly decreased ability to leam new material. Most often patients 
exhibit both forms of memory impairment but they can also be present independently. 
Besides memory impairment, one or more other cognitive dysfunctions are present in 
dementia of the Alzheimer's Type. These cognitive dysfiinctions are manifested as aphasia, 
apraxia, agnosia or disturbance in executive fimctioning. Aphasia is a language dysfimction 
characterized by difficulty in generating the names of individuals and objects. Speech 
becomes vague with frequent use of words without definite reference. Apraxia is an 
impairment in execution of motor tasks without damage to the motor and sensory fiinctions 
and comprehension of the task. Agnosia is the inability to identify or recognize objects 
despite intact sensory fimctions. Disturbances in executive functioning encompass 
impairment of abstract thinking and the ability to plan and execute complex behaviors. 
Sensory and motor fimctions in Alzheimer's disease are usually conserved (Haxby, 1990). 
The diagnosis of this disease depends on the symptoms described above and 
exclusion of other causative factors that can result in the same symptomatology. The 
conditions that need to be excluded encompass disorders such as other central nervous 
system conditions (e.g., cerebrovascular disease, brain neoplasmas, subdural hematoma), 
metabolic abnormalities (e.g., hypothyroidism , hypovitaminosis) and intoxications (Beal et 
al., 1997; American Psychiatric Association, 1997). In spite of the above diagnostic criteria, 
the definitive diagnosis of Alzheimer's disease can be determined only postmortem by 
pathohystological examination of the brain tissue and finding the characteristic changes that 
are further discussed below. 
Neuropathology of Alzheimer's Disease 
Gross Brain Neuropathology 
Patients with Alzheimer's disease develop more severe atrophy of frontal, temporal 
and parietal cortex than age-matched individuals (Jolles et al., 1990; Khachaturian and 
Rodebaugh, 1996). This cortical atrophy can be manifested by: I) decrease in cortical 
surface area, 2) decrease in cortical thickness ('laminar atrophy'), 3) decrease in brain weight 
and volume, and 4) narrowing of the gyri and enlargment of sulci and 5) enlargment of 
cerebral ventricles. 
Cortical atrophy characterized by decreased surface area of all lobes is more 
pronounced in early onset than in late onset cases whereas more focal decrease in surface 
area was detected in late onset cases (Hubbard and Anderson, 1981). The thickness of the 
neocortex is significantly decreased in AD patients but it is similar to that found in normally 
aged brains (Kemper, 1984; Hansen et al., 1988). It has been proposed that the reported 
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cortical atrophy, especially in the earlier stages of AD, could be mainly due to a decrease in 
cortical surface area rather than decrease in cortical thickness (Hauw et aL, 1990). Hauw et 
al. suggested that the cortical atrophy was due to the loss of neuronal columns and fibers 
(that are positioned perpendicular to the cortex surface) which would result in decreased 
cortical surface, and was not due to the loss of selective layers of the cortex (laminar loss) 
which would cause a decrease in cortex thickness (Hauw et al., 1990). In fact, it was 
demonstrated that mental decline correlated with the decrease of cortical surface, not the 
thickness of the cortex (Duyckaerts et al., 1985; Hauw et aL, 1987). However, in most severe 
cases of AD, when compared to age-matched controls, cortical thickness is significantly 
decreased; furthermore, it is the most prominent in the temporal cortex which appears to be 
significant because AD pathologic changes in the temporal region are well documented 
(HauwetaL, 1990). 
It has been suggested that ventricular and sulcal enlargement in AD patients is 
somewhat greater compared with elderly controls (Arai et aL, 1983). Regional cortical 
atrophy manifested by enlargement of sulci and ventricles has been proposed to be more 
specific and more important in AD (Jolles et aL, 1990) than diffuse, more generalised 
enlargement of sulci and ventricles which can also be present in a variety of neurological and 
systemic conditions (TerBrugge et aL, 1987; Jolles et aL, 1990). The importance of these 
regional changes is supported by studies that reported greater temporal lobe atrophy as 
revealed by dilation of the hippocampal fissure and ventricular enlargement in AD brains 
than in control subjects (George et al., 1987; fCido et al., 1987). Additionally, it was 
proposed that this focal change is the earliest sign of AD (George et aL, 1987; Kido et aL, 
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1987). Indeed, the severity of dementia have been shown to be highly correlated with the 
degree of this focal ventricular and. sulcal enlargement (de Leon et al., 1980; Earnest et al., 
1979; George et al., 1983; Jacoby et al., 1980). 
Regional specificity of the cortical atrophy was further supported by findings of the 
changes in volume of the cerebral cortex. In AD patients cortical volume was significantly 
reduced when compared to age-matched individuals, with the most prominent reduction in 
volume noted in medial temporal structures such as the hippocampus (Double et al., 1996). 
This particular volume reduction was related to severity and progression of the disease. 
Several types of changes in white matter demonstrated by computerized tomography 
(CT) and magnetic resonance imaging (MRI) are collectively referred to as leukoaraiosis. 
Leukoaraiosis encompasses: 1) periventricular low-density lesions on CT, 2) periventricular 
hyper-intensity lesions on CT, and 3) periventricular hyper-intensity changes on MRI 
(Ishijima et al., 1996). CT studies have shown that white matter changes in the form of 
lucencies (low density lesion) were more common in AD patients than in control subjects 
(George et al., 1986; Leys et al., 1990). Furthermore, MRI investigations of AD brains 
found halo-shaped hyper-intensity foci of white matter (suggestive of water accumulation 
and/or demyelination) surrounding the lateral ventricle (Fazekas et al., 1987; Petrovic et al., 
1990). Subsequent examinations of periventricular white matter have shown diffuse loss of 
myelin sheets, axons, oligodendroglia and astrocytic gliosis (Brun et al., 1990; Leys et al., 
1990). These changes of white matter were also shown to be associated with the degree of 
cognitive impairment in AD patients (Brun et al., 1990; Ishijima et al., 1996). 
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Pathohistology 
Although assessment of the gross cerebral features may suggest AD, the final 
neuropathological diagnosis depends on microscopic examination of the brain tissue. The 
pathological hallmarks of Alzheimer's disease are neuronal loss, extracellular neuritic 
plaques, intracellular neurofibrillary tangles , and amyloid angiopathy. 
Two major subtypes of neuritic plaque are recognized: classic neuritic plaque and 
diffuse plaque. Classic neuritic plaque consists of a dense central core of radiating 
amyloid fibrils surrounded by a rim of abnormal axonal and dendritic processes, reactive 
microglia and astrocytes. The diffuse plaques that can not be detected using routine stains 
(Congo red, silver) have been observed after an immunohistochemical reaction with 
antibodies to P-amyloid. Most diffuse plaques are not associated with abnormal neurites or 
reactive glia. Ultrastructural observations revealed little or no fibrillary amyloid in these 
lesions suggesting that diffuse plaques are an early stage in classic neuritic plaque formation 
(Yamaguchi et al., 1990). 
The second pathohistological hallmark of AD is the presence of neurofibrillary 
tangles that appear in neuronal cell bodies and in altered neurites as dense bundles of fibers. 
Tangles consist of paired helical filaments (PHFs) which are composed of tau protein (Kosik 
et al., 1986; Nukina and Diara, 1986; Kosik et al., 1988). Immunocytochemical studies have 
shown that antibodies raised against tau protein have recognized PHFs in tissue sections and, 
conversely, that antibodies raised against isolated preparations of PHFs recognized the tau 
protein. The observation that some antibodies to tau protein react with PHFs much more 
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strongly after dephosphorylation of tissue sections suggests that certain epitopes within PHFs 
may be abnormally phosphorylated (Grundke-rqbal et aL, 1986). 
The third neuropathological feature of AD is amyloid angiopathy or deposition of 
P-amyloid protein in walls of meningeal and cortical blood vessels and around cerebral 
vasculature (Wisnienwsld et al., 1992b). These vascular (5-amyloid deposits assume three 
distinct morphological types: 1) a semicircular thickening of the vascular wall caused by a 
large amount of fibrilar P-amyloid deposits, 2) tuberlike amyloid deposits, and 3) amyloid 
stars with a radial arrangement of P-amyloid fibrils (Wisniewski and Wegiel, 1992). Such 
perivascular depositions of B-amyloid cause amyloid angiopathy characterized by 
endothelial degeneration and obliteration of the vessel lumen (Wisniewski and Wegiel, 
1992). fi-amyloid angiopathy is also accompanied by neuronal degeneration and appearance 
of reactive astrocytes (Wisniewski et al., 1992). 
^Amyloid Protein 
Amyloid is a general term in pathology that designates deposits of 5-10 nm 
proteinaceus fibrils which accumulate progressively in the extracellular spaces of tissue and 
vasculature. In the case of AD a specific protein that is deposited in the core of neuritic 
plaques and the walls of cerebral vasculature is designated as P amyloid protein (P A4). 
Amino acid sequencing has shown that PA4, originally isolated from meningeal 
blood vessels (Glenner and Wong, 1984), is essentially the same as the senile plaque PA4 
(Masters et al., 1985). Molecular cloning has revealed that P A4 is a small fragment of a 
much larger amyloid precursor protein (APP). The pA4 molecule is a 32- to 42-amino acid 
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peptide, part of which forms the hydrophobic transmembrane domain in the COOH- terminal 
portion of APP (Kang et al., 1987). 
APP is normally cleaved by protease-APP secretase within 43-amino acid of PA4 to 
produce a large secreted derivative ending at amino acid 16 of PA4 and a small, membrane 
associated, COOH- terminal derivative beginning at amino acid 17 of |3A4 (Esch et aL, 
1990). A complex set of 8- to 12-kD COOH- terminal derivatives of APP have been shown to 
exist in human brain and peripheral tissues. The two largest COOH-derivatives have the 
entire (3 A4 insert at, or near, their NH2- terminus and are likely the intermediates in the 
pathway leading to amyloid deposition. Different brain regions have roughly equivalent 
levels of the various 8- to 12-kD derivatives, whereas each peripheral tissue has relatively 
low levels of the larger, potentially amyloidogenic forms (Estus et al., 1992). The discovery 
of the production of these complex 8- to 12-kD COOH- terminal derivative sets as a result 
of APP degradation suggested that APP can be cleaved in some alternative proteolytic 
pathways. 
Three distinct pathways of APP proteolysis have been demonstrated using APP 695 
deletion mutant that produces the normal set of COOH- terminal derivatives and shortened 
secreted derivatives (Golde et al., 1992; Haass et al., 1993a; Haass et al., 1993b). These 
researchers found that, in the secretory pathway, mediated by APP secretase, cleavage of the 
APP occurred at a single site within the P A4 to generate one secreted derivative and one 
nonamyloidogenic COOH- terminal fragment. On the other hand, in the 
endosomal-lysosomal pathway, a complex set of COOH- terminal derivatives that includes 
the potentially amyloidogenic forms was produced (Todd et al., 1992). The previous study 
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which demonstrated elevated levels of lysosomal proteases in neuritic plaques (Cataldo and 
Nixon, 1990) supported the feasibility of this finding and. the importance of the lysosomal 
pathway in amyloidogenesis and pathogenesis of AD. 
Subsequent work has shown that cultured cells produced PA4 during normal 
metabolism (Haass et al., 1992), demonstrating that an aberrant pathway may not be 
necessary for amyloidogenesis. Thus, it has been suggested, that lysosomes may not be 
directly required and may not play a predominant role in formation of Pa4 (Haass et al., 
1993a, 1993b). Such findings favor the current hypothesis that PA4 may be generated in 
acidic intracellular compartments (Haass etal., 1993a, 1993b). 
Different forms of APP that contain PA4 are derived from a single gene by 
alternative mRNA splicing. These PA4 precursors contain 695, 751 and 770 amino acids 
and differ from one another primarily by the presence (in case of APP 770 and APP 751) or 
absence (in case of APP 695) of a Kunitz-type protease inhibitor insert (Kithaguchi et al., 
1988; de Sauvage and Octave, 1989; Ponte et al., 1988; Tanzi et al., 1988). APP is expressed 
at high levels in many different tissues throughout the body. In most tissues, APP 770 is the 
most abundant, whereas in the CNS, the transcript lacking the protease inhibitor insert (APP 
695) is predominant. The ratio of amyloidogenic and nonamyloidogenic fragments released 
by APP degradation may depend on the balance of APP's intrinsic protease inhibitory 
property, exposure to the proteases in the microenviroment (Aisen and Davis, 1994), and 
overexpression of APP. The significance of overexpression of the APP gene was first 
elucidated in patients with Down's syndrome (trisomy 21) when the gene encoding APP was 
mapped to chromosome 21 (Davies and Tilghman, 1993). Early onset of dementia in 
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patients with Down's syndrome is characterized by P-amyloid deposition and development 
of diffuse and neuritic plaques. Such observations led to the conclusion that the process of 
P-amyloid deposition is a central event in AD pathogenesis (Davies and Tilghman, 1993). 
The evidence further supporting the theory of B-amyloid deposition as the primary 
pathological process was the identification of pathogenic mutations in the B-amyloid 
precursor protein gene that were linked to autosomal dominant forms of familial AD (Hardy, 
1994; Hanger et al., 1992). Transgenic mice overexpressing human mutant B-amyloid 
precursor protein progressively developed pathological hallmarks similar to AD including 
P-amyloid deposits, formation of neuritic plaques and association of reactive microglia and 
astrocytes with amyloid deposits (Games et al., 1995). Although synaptic loss and 
degenerating neurons in transgenic mice accompany the B-amyloid deposition, the 
mechanisms involved in B-amyloid mediated neuronal degeneration are not well understood. 
However, it is known that the neurotoxicity of B-amyloid is related to amino acids 25-35 
(B25-35) of the full-length B-amyloid peptide (Bl-43) (Mattson et al., 1992; Yanker et al., 
1989). Additionally, toxicity of B-amyloid depends, at least in part, on its aggregation state 
(Pike et al., 1991; Pike et al., 1993). 
Astrocytes and Alzheimer's Disease 
The morphological observations of a close association between reactive glia cells and 
neuritic plaques suggest reactive glial cells as a prominent component of Alzheimer's disease 
pathology. Astrogliosis manifested by activation of astrocytes is a common form of 
astrocytic response to injury and cellular necrosis in the CNS (Montgomery, 1994). The 
most distinctive characteristic of activated astrocytes , also referred to as reactive astrocytes. 
II 
is an increase in glial fibrils composed of glial acidic fibrillary protein (GFAP), demonstrated 
by an increased immunocytochemical staining for GFAP (Montgomery, 1994). Interestingly, 
a marked increase in astrocytic GFAP levels has also been detected in the brain of AD 
patients (Haga et al., 1989; Ogata et aL, 1992). One of the sites found to have a significantly 
high GFAP immunoreactivity is neuritic plaque (Farinelli and Nicklas, 1992). It has been 
suggested that glial cells surrounding neuritic plaques are also involved in the removal of 
debris from degenerated neurites (Rozemuller et al., 1989; Wisniewski and Wegiel, 1992), 
the synthesis and deposition of (3-amyloid (Wisniewski and Wegiel, 1992), or the isolation of 
P-amyloid from neuropil by astrocytic processes (Wisniewski and Wegiel, 1992). 
A variety of cellular metabolic processes in reactive astrocytes are known to be upregulated. 
An example is the synthesis of proteins (e.g., cytokine synthesis) with potent biological 
effects (Montgomery, 1994; Norenberg et al., 1979). Various factors have been identified to 
have a regulatory effect on activation of astrocytes (Montgomery, 1994). For example, an in 
vitro study of astrocytic cultures has shown that B-amyloid stimulates astrocytic release of 
interleukin-1 (IL-1) and basic fibroblast growth factor (bFGF) (Araujo and Cotman, 1992). 
This study suggests the possibility that reactive astrocytes may be responsible for high levels 
of cytokine immunoreactivity observed in AD (Gomez-Pinilla et al., 1990; Griffin et al., 
1989; Hara et al., 1989). Therefore, it is possible that B-amyloid may also affect some other 
astrocytic functions. 
Astrocytic Role in Nitric Oxide (NO) Production 
Astrocytes isolated from am'mals are uniquely equipped with both constitutive Nitric 
Oxide Sythase (cNOS) and inducible NOS (iNOS). Astroglial cNOS can be activated by 
glutamate, noradrenalin and calcium ionophores, followed by a significant increase in 
cGMP. In contrast, astroglial iNOS is stimulated by cytokines such as EL-1p, IFN-Y and 
TNF-a. Human astrocytes have also been reported to release nitric oxide (NO) upon 
stimulation with a combination of IFN-y and IL-1|3 (Lee et al., 1993). 
EL -1 immunoreactivity levels in temporal lobe homogenates of AD patients have 
been shown to be elevated in comparison to age-matched controls. An immuno-histological 
study also showed a 30 fold increase in the number of EL-1 immunoreactive glial cells in AD 
brains. Most of the immunoreactive glia were microglia, but numerous astrocytes associated 
with neuritic plaques were also intensely EL-l immunoreactive (Griffin et al.,I989). 
Association of EL-I, bFGF and T- cells with neuritic plaques suggests some specific 
roles played by glial cells in the pathogenesis of Alzheimer's disease (AD) (Gomez-Pinilla 
et al., 1990; Griffin et al., 1989; Haga et al., 1989). One of the suggested specific astrocytic 
roles in AD pathogenesis is their capacity to release nitric oxide as a response to cytokine 
(IL-ip, IFN-y and TNF-a) stimulation (Murphy et al., 1993). At high concentrations, NO has 
been shown to exhibit cytotoxic effects on a variety of cell types including neurons 
(Bruhwyler et al., 1993). However, NO also plays an important role in the regulation of 
cerebrovascular blood flow. The coupling between cerebral metabolic function and cerebral 
blood flow is one important regulatory feature of the cerebral blood flow. NO released by 
neurons, vascular endothelium and astrocytes appears to be the key factor in this coupling 
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process (Bruhwyler, 1993; Whal etal., 1993). Therefore, interactions of P-amyloidand 
various cytokines implicated in AD pathogenesis and their effect on astrocytes could be very 
important for understanding of (3-amyloid neurotoxicity in AD. Furthermore, possible 
|3-amyloid modulation of astroglial release of NO is also important because nitric oxide 
plays a role in the regulation of cerebrovascular function. 
Direct neuronal effects of P-amyloid have been extensively studied; however, less 
work has been done describing P-amyloid effect on astrocytes and microglial cells which are 
observed as a prominent component of the neuritic plaques. In vitro studies have shown that 
astrocytes and microglial cells react to P-amyloid by changing morphology and releasing 
EL-l and bFGF (Araujo and Cotman, 1992). In addition, it has been shown that P-amyloid 
significantly enhances microglial release of nitric oxide (NO) (Goodwin et al., 1995). 
Astrocytes are also capable of releasing NO when stimulated by various cytokines (DL-ip, 
IFN-g and TNF-a) and glutamate. However, it is not well known whether p -amyloid 
modulates cytokine-induced astroglial release of NO. 
Considering the anatomical location and abundance of astrocytes in the CNS, their 
change of cellular metabolism in response to a wide variety of environmental changes in the 
CNS, and their capability for release of nitric oxide, the effects of interaction among 
astrocytes, cytokines, and P-amyloid would have significant implications for CNS 
pathophysiology. 
Astrocytic Role in Glutamate and Glucose Metabolism 
Glutamate is the most abundant excitatory neurotransmitter in the mammalian CNS. 
It has been implicated in the processes of learning and memory (Maragos et al., 1987) as 
well as the pathogenesis of AD (Palmer et al., 1990). Neurochemical studies of 
glutamatergic neurons in Alzheimer's disease revealed alterations in the glutamatergic 
systems (Maragos et al., 1987). More specifically, a decreased number of glutamate 
receptors in AD patients was detected when compared to age-matched controls (Greenmayre 
et al., 1985). The largest decrease of glutamate receptors was seen in the outer cortical 
layers and hippocampus (Greenmayre et al., 1985) where the greatest concentration of 
neuritic plaques was noted. Additional evidence supporting the loss of the glutamatergic 
nerve terminals came from post-mortem studies of the neocortex. In advanced AD patients , 
both cerebral glutamate concentrations and sodium-dependent aspartate binding were 
decreased compared to age-matched controls (Maragos et al., 1987). The connection 
between the temporal nature of neuronal death and changes in the glutamatergic system of 
AD patients was established with the discovery of a correlation between the decline in 
cognitive test scores of AD patients and the concentration of glutamate in their cerebrospinal 
fluid (Maragos et al., 1987). 
The exact cause of neuronal degeneration in AD is unknown, but the dysfunction of 
the glutamatergic system is a strong candidate (Maragos et al., 1987). When the glutamate 
receptor agonist (NMDA) was applied to the cerebral cortex of rats, a retrograde neuronal 
degeneration was found in areas that are known for the presence of histopathological 
features in AD patients (Sofroniev and Pearson, 1985). Furthermore, in human fetal spinal 
cord cultures, glutamate induced the formation of various paired helical filaments with some 
of them nearly identical to paired helical filaments found in AD (DeBoni and McLachlan, 
1985). These studies support the neurotoxic hypothesis of AD pathogenesis that is based on 
glutamate action as endogenous excitatory amino acid toxin (Maragos et al., 1987). 
Two tj^es of toxic changes induced by glutamate in vivo are acute swelling of 
neuronal bodies and dendrites and delayed neuronal degeneration (Choi, 1988). A NMDA 
receptor, one of the three types of glutamate membrane receptors, plays the key role in 
mediating glutamate toxicity (Choi, 1988). Acute neuronal swelling occurs early in the 
glutamate exposure and it is dependent on extracellular Na' and CI" because Na" influx leads 
to membrane depolarization and secondary influx of CI' and water, resulting in neuronal 
swelling (Choi, 1987). Delayed neuronal degeneration occurs later, and it is mediated by 
excessive Ca"" influx and Ca"" release from intracellular stores which elevate cytosolic Ca" 
that, in turn, can activate numerous intracellular processes (e.g. protein kinases, 
endonucleases) (Choi, 1987; Meldrun and Garthwaite, 1990). Both types of glutamate 
induced toxic changes can lead to irreversible neuronal injury, but the Ca"-dependent 
delayed neuronal degeneration is more important at lower exposures to glutamate and hence 
more likely to predominate in pathological conditions (Choi, 1987, 1988). 
Normally, extracellular levels of glutamate rise to high levels only briefly during 
synaptic transmission, with this rise being localized within the synaptic cleft (Choi, 1988; 
Nichols and Attwell, 1990). After its release from the nerve terminal, glutamate is removed 
from extracellular space by 1) transport back to the nerve terminal, and 2) uptake into 
astrocytes (Nichols and Attwell, 1990; Palmer et al., 1990). Plasma membrane glutamate 
carriers that are present in neuronal presynaptic membrane, and astrocytic plasma membrane 
are very similar (Kanner, 1988). Plasma membrane glutamate transporters have low 
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specificity for glutamate as they caa also transport L- and D-aspartate. Nevertheless, they 
possess a high afiSnity for glutamate which makes them ideal carriers at the physiological 
levels of glutamate (Nichols and Attwell, 1990). 
It seems that astrocytes play a more prominent role in the removal of extracellular 
glutamate. A study with radioactive markers showed that most of the exracellular glutamate 
is taken up by astrocytes rather then by neurons (McLennan, 1976). The glutamate taken up 
by astrocytes is then converted by a glia cell-specific enzyme, glutamine synthetase, into 
glutamine which can, in turn, be used by neurons for glutamate synthesis (Farinelli and 
Nicklas, 1992). The essential role of astrocytes in protection against glutamate neurotoxicity 
and maintenance of low extracellular levels of glutamate was further supported by in vitro 
experiments (Rosenberg et al., 1992). This study clearly demonstrated a significant increase 
in neuronal susceptibility to glutamate toxicity when neurons were co-cultured with 
relatively few astrocytes compared to astrocyte-rich neuronal co-cultures (Rosenberg et al., 
1992). Neuronal death, however, occurred even in astrocyte-rich co-culture when glutamate 
uptake into astrocytes was blocked, suggesting the importance of astrocytic glutamate uptake 
in preventing the glutamate neurotoxicity (Rosenberg et al., 1992). These findings are 
important in view of the evidence that glutamate uptake decreases in the brains of AD 
patients (Kanai et al, 1993). 
The accumulation of glutamate in astrocytes, against its concentration gradient due to 
glutamate uptake transport, is an energy dependent process (Swanson, 1992). Consequently, 
astrocytes require ATP energy to maintain the glutamate uptake process (Swanson, 1992; 
Nichols and Attwell, 1990; Ogata et al., 1992). A close relationship between glutamate 
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uptake and glucose availability has been shown in both conditions, in vitro and in situ 
(Swanson, 1992; Swanson et al., 1994). As long as glucose is available, astrocytes can 
maintain the production of sufficient ATP levels and continue giutamate uptake (Swanson, 
1992; Swanson et al., 1994). The presence of glutamate-coupled glucose utiUzation in 
astrocytes (Swanson et al., 1990; Pellerin and Magistretti, 1994) further suggests the 
interdependency of glucose and giutamate metabolisms in astrocytes. 
In summary, reactive astrocytes are a prominent component of the neuritic plaque, a 
pathohistological hallmark of AD. Reactive astrocytes respond to extracellular environment 
changes and insults by changing their cellular metabolism. In response to P-amyloid, 
astrocytes are known to release IL-1, and EL-l immunoreactivity was detected around 
neuritic plaques. Astrocytes are also capable of NO production when stimulated with 
cytokines. This is important because NO is a key factor in regulation of cerebral blood flow 
and, in addition, it can be neurotoxic when present in high concentrations. Given the 
importance of NO in regulation of blood flow and astrocytic capability to release NO as well 
as their responsiveness to various stimuli (e.g. P-amyloid), the first study of this thesis 
examined the P-amyloid modulation of cytokine induced NO release from astrocytes by 
exposing cultured astrocytes to P-amyloid peptide (P25-35) alone or in combinations with 
EL-ip, TNF-a and IFN-y. 
Another astrocytic function that can claim a pivotal role in development of AD 
pathology is maintenance of extracellular giutamate levels. Glutamatergic system 
dysflmction and giutamate neurotoxicity have been implicated in AD pathology, p-amyloid 
has been shown to increase the vulnerability of cultured neurons to glutamate-induced 
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excitotoxic damage, and it is likely that the interaction between P-amyloid and astrocytes 
would lead to dysfunction of the astrocytic glutamate uptake system, hence increased 
glutamate toxicity. In light of the importance of astrocytes described above, in the glutamate 
uptake process and the evidence supporting the accumulation of (3-amyloid as a primary 
pathological process in. AD, the second study of this thesis explored the effect of B-amyloid 
on astrocytic glutamate and glucose uptakes in vitro. 
Explanation of dissertation format 
This dissertation is composed of two papers. The papers are preceded by a general 
introduction and followed by a general discussion which contains a summary and 
interpretation of the entire body of work. References firom the general introduction, 
discussion as well as both papers are located at the end of the general discussion chapter. 
The first paper has been submitted to Glia by Parpura-Gill, A. and Uemura, E. The 
second paper has been published in Brain Research where it was submitted by Parpura-Gill, 
A., Beitz, D. and Uemura, E. 
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THE EFFECTS OF P-AMYLOED ON ASTROGLLVL RELEASE OF NITRIC 
OXIDE MEDIATED BY IL-IB, TNF-A, AND IFN-Y 
A paper submitted to Glia 
Aleksaiidra Parpura-Gill and Etsuro Uemura 
Abstract 
The effect of cytokines such as EL-IB, TNF-a, and CFN-y on astrocytic nitric oxide is 
well documented; however, the effects of B-amyloid on astrocytes for their 
cytoldne-mediated release of nitric oxide is not established. In the present study, astrocytic 
release of nitric oxide was studied following exposure to B-amyloid peptide (B25-35) in 
combinations with EL-IB, TNP-a or IFN-y. None of the cytokines induced an increase in 
nitrite levels (nmol/mg protein) in astrocytic culmres by themselves. However, EFN-y 
combined with IL-IB or TNF-a induced a significant increase in nitrite levels. Although 
both IL-IB and TNF-a were effective costimulatory factors, the combination of EFK-y and 
EL-IB was more effective in increasing nitrite levels in cultures than the combination of 
EFN-y and TNF-a. B25-35 completely blocked the increase in nitrite levels by IFN-y and 
TNF-a, whereas B25-35 partially blocked the effect of IFN-y and IL-IB. The effect of 
cytokines (IFN^ + EL-IB, EFN-y + TNF-a) on nitrite levels in the astrocytic supernatant was 
substantially reduced by N^-monomethyl-L-arginine (NMMA), suggesting that the effect of 
B25-35 and cytokines was due to a change in nitric oxide synthase activity and the release of 
nitric oxide. These findings warrant a further study to determine how the modulatory action 
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of B-amyloid on cytokine-mediated astrocytic release of nitric oxide affects neuronal 
fimctions in AD patients. 
1. Introduction 
In Alzheimer's disease (AD), the accumulation of B-amyloid is a characteristic 
feature seen in certain areas of the brain (Beyreuther et al., 1991; Marotta et al., 1992). 
B-amyloid deposition can occur in the absence of neuronal degeneration in patients with AD. 
Non-compacted, diffuse deposits of B-amyloid are not always associated with dystrophic 
neurites and reactive astrocytes. In contrast, the dense-core type (or matured) neuritic 
plaques are almost always associated with dystrophic neurites (Hardy and Allsop, 1991; 
Bceda et al., 1990). These observations suggest that neuritic plaques progress from the diffuse 
inert form to the B-pleated amyloid plaque. B-amyloid deposits also occur around cerebral 
vasculature (Wisniewski et al., 1992). Such perivascular depositions of B-amyloid cause 
amyloid angiopathy characterized by endothelial degeneration and obliteration of the vessel 
lumen (Wisniewski and Wegiel, 1992). B-amyloid angiopathy is also accompanied by 
neuronal degeneration and reactive astrocytes (Itagaki et al., 1989; Wisniewski et al., 1992). 
At the site of B-amyloid deposits in the AD brain, reactive astrocytes and their 
processes are at the margins of the deposits (Wisniewski and Wegiel, 1992). Such 
morphological observations led to the suggestion that astrocytes surrounding B-amyloid are 
involved in the dispersal, removal or isolation of B-amyloid from the neuropil. However, 
reactive astrocytes are known to upregulate many proteins with potent biological effects 
(Norenbert, 1994), and astrocytic neurotrophic factors appear to support regeneration and 
recovery of damaged neurons (Murphy and Grzybicki, 1996). Therefore, it is possible that 
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B-amyloid changes the intercellular environment by altering astrocytic flmctions. For 
example, it was shown that 6-amyloid stimulates astrocytic release of interleukin-l (IL-l) 
and basic fibroblast growth factor (bFGF) (Araujo and Cotman, 1992). This in vitro study 
suggests the possibility that reactive astrocytes are responsible for the high IL-l and bFGF 
immunoreactivity observed in AD, particularly around neuritic plaques (Gomez-Pinilla et al., 
1990; Griffin et al., 1989). Expression of potential mediators of reactive gliosis, such as 
bFGF, which astrocytes synthesize and respond to by increased GFAP levels, has also been 
shown in cultured astrocytes (McMillian et al., 1994). Interestingly, a marked increase in 
GFAP levels has also been detected in the brain of AD (Harpin et al., 1990; Panter et al., 
1985). One of the sites found to have high GFAP immunoreactivity was neuritic plaques 
(Du% et al., 1980). 
Astrocytes proliferate in response to EL-lB and release TNF-a (Lee et al., 1993). 
Cytokines, such as EL-IB, TNF-a, and EFN-y, have been shown to induce release of nitric 
oxide from a variety of glial cells including astrocytes (Lee et al., 1993; Murphy et al., 1993). 
This cytokine-mediated release of nitric oxide by astrocytes is important because nitric 
oxide is a potent vasodilator of cerebral blood vessels (Moncada et al., 1991) and levels of 
nitric oxide released by activated astrocytes are sufficient for induction of smooth muscle 
relaxation and subsequent dilation of cerebral vasculature (Faraci and Brian, 1994). 
Astrocytes have their endfeet processes in close proximity to the endothelial cells of cerebral 
capillaries and are believed to play a role in regulation of endothelial cells (Montgomery 
1994; Risau and Wolburg, 1990). Thus, astrocytic endfeet processes are an important 
element that regulates nitric oxide-mediated relaxation of cerebral vasculature. 
Although the effect of cytokines such as EL-lB, IFN-y and TNF-a on astrocytic release 
of nitric oxide is well documented (Murphy et aL, 1993), the effect of the particular cytokine 
combination (IFN-y + TNF-a) on induction of astrocytic nitric oxide is not known. Also, the 
effects of B-amyloid on astrocytes for their cytokine-mediated release of nitric oxide is not 
established. In the present study astrocytic release of nitric oxide was studied following 
exposure to B-amyloid peptide (B25-35) in combinations with EL-IB, TNF-a or IFN-y. 
2. Materials and Methods 
2.1 Synthesis of fi-amyloid (fi25-35) and Scrambled Peptide 
Scrambled peptide and B-amyloid (B25-35) peptides were synthesized and purified by 
the University of Iowa Protein Structure Facility. The scrambled peptide has the following 
sequence: H-He-Met-Leu-Gly-Asn-Gly-Asn-Gly-Ala-Ser-IIc-Gly-OH (Mattson et aL, 1992). 
Cultured neurons were exposed to B-amyloid by the method described previously (Goodwan 
et aL, 1997; Parpura-Gill et aL, 1997). Briefly, scrambled peptide and S25-35 peptides were 
dissolved in sterile tissue culture water (Sigma, pH 7.2) at a concentration of Img/ml, and 
aliquots were stored at -20°C. Culture wells were coated with B25-35 or scrambled peptide 
by placing the peptide solutions (20 fil of a stock solution) onto the culture wells. Tissue 
culture wells were left to dry overnight at room temperature after which they were used for 
astrocyte cultures. 
2.2 Astrocyte Culture 
Primary glial cultures were prepared from the hippocampus of P2-5 Sprague-Dawley 
rats. The hippocampus was dissected and mLxed glial cultures were grown in flasks 
containing: Eagle's minimum essential media supplemented with 10% heat inactivated fetal 
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bovine serum, 40 mM glucose, 2 mM L-glutamine, 1 mM pyruvate, 14 mM sodium 
bicarbonate, penicillin 100 i.u./ml and streptomycin 100 jig/ml (pH 7.35) (Parpura-Gill et al., 
1997). At confluency, flasks were shaken manually and the media containing mainly 
non-adherent microglial cells were removed. Fresh media were added to the adherent cells 
and flasks were shaken overnight (200 rpm @ 37°C). The media were removed once again 
and adherent cells were scraped off the bottom of the flasks and mechanically dissociated. 
This cell suspension was plated into new flasks for 30 min. to allow the remaining microglia 
to attach. Non-adherent cells were collected and plated onto 96-well tissue culture plates. 
Purity of the astrocyte cultures, as determined by GFAP immunocytochemistry staining, was 
greater than 95%. 
Astroglial release of nitric oxide was examined by exposing astrocytes to B25-35 
coated on to the surface of culture wells and cytokines (EL-IB, TNF-a and EFN-y) in the 
media. Although B-amyloid found in the AD neuritic plaques is immobile and insoluble, 
most previous tissue culture studies have sought to determine B-amyloid's effects by 
solubilizing it or suspending it in culture medium. The alternative method used in our study 
(Goodwin et al., 1995; Parpura-Gill et al., 1997) not only ensures that most cells are exposed 
to B-amyloid, but it also prevents any possible physical cellular damage by aggregated and 
mobile B-amyloid. At postplating day 6, IL-IB (100 U/ml, Boehringer-Mannheim), IFN-y 
(100 U/ml, Gibco BRL), TNF-a (100 U/ml, Genzyme) and their combinations (IFN-y + IL-IB 
or EFN-y + TNF-a) were added to the astrocyte cultures. At postplating day 8, the culture 
media were collected for nitrite analysis. Concentrations of nitrite, a nitric oxide metabolite. 
in the media were used as a measure of nitric oxide generation. Each experiment was 
performed in a mimmum of two wells per condition and was replicated at least four times. 
To investigate whether nitrite measured in the media was of nitric oxide origin, 
astrocytes were exposed to N^-Monomethyl-L-arginine (NMMA) (Calbiochem), a 
competitive inhibitor of nitric oxide synthetase (Hibbs et al., 1988). At postulating day 6, 
cultured astrocytes were exposed to cytokines [EL-lB (100 U/ml), IFN-y (100 U/ml), TNF-a 
(100 U/ml) and their combinations (IFN-y + IL-IB or IFN-y TNF-a)] with addition of 500 
nM NMMA. At postplating day 8, tissue culture media were tested for nitrite levels. Each 
experiment was performed in a minimum of two wells per condition and was replicated at 
least three times. 
Nitric oxide release from astrocytes was initially studied by plating cells onto culture 
wells coated with or without 1325-35. In the subsequent experiment, the effects of scrambled 
control peptide on astrocytic release of nitric oxide was assessed. Astrocytes were cultured 
in culture wells either coated with scrambled peptide or uncoated. At postplating day 6, 
IL-IB (100 LT/ml), IFN-y (100 U/ml), TNF-a (100 U/ml) and their combinations (IFN-y -i-
IL-IB or IFN-y + TNF-a) were added into the culture media for 2 days after which, media 
were collected and assayed for nitrite content. Each experiment was performed in a 
minimum of two wells per condition and was replicated at least four times. 
2.3. Nitric Oxide Assay 
Nitrite levels were determined by a colorimetric assay based on the Griess reaction. 
Equal volumes of Griess reagent (0.05% N-(l-naphtyl)ethylenediamine dihydrochloride and 
0.5% sulfanilamide in 2.5% phosphoric acid) and either samples or standards were mixed 
and their absorption read on an Eh'sa reader at 550 nm (Molecular Devices, Vmax). 
Concentrations were expressed as a ratio of nitrite level per milligram of total cell protein in 
a culture. As an additional precaution, percent change of each nitrate/protein ratio of 
experimental groups from the nitrite/protein ratio of the control cultures was calculated and 
used in statistical analyses. The percent change was calculated to remove the potential 
artifactual effects due to differences in cell proliferation among cultures. 
2.4. Cellular Protein Assay 
Cellular protein assay was used as an index of cell proliferation. In the first 
experiment, after media collection, astrocyte cultures were washed three times with 0.1 M 
PBS and subsequently air dried. Total cell protein content was determined using the 
Bio-Rad protein assay kit. Absorption was read on an Elisa reader at 630 nm with reference 
to 490 nm. In the subsequent experiments astrocyte cultures were washed three times with 
0.1 M PBS and were subsequently lysed with O.IN NaOH overnight. Total cell proteins were 
determined in cell lysates using the standard protocol for microtiter plates of the Bio-Rad 
protein assay kit. Absorption was read on an Elisa reader at 595 nm. Total cell proteins 
were expressed in milligrams and treatment related changes were statistically evaluated. 
2.5. Statistical Analysis 
Two way analysis of variance (ANOVA) was performed. Levels of nitrate production 
were expressed as percentage of reduction or increase from the control. Tukey's B posthoc 
procedure was used to determine any intertreatment differences. 
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3. Results 
3.1. Effect Of Ji25'35 On Astrocytic Release Of Nitric Oxide Mediated By EL-lfi, TNF-a 
And [FN-y 
To examine whether B25-35 affects cytokine-induced astroglial release of nitric 
oxide, astrocytes cultured on B25-35 peptide for 6 days were subsequently exposed to 
cytokines (CL-IB, TNF-a and IFN-Y). Astrocytes not exposed to either B25-35 peptide or 
cytokines served as controls. Astrocytes exposed to B25-35 had significantly higher content 
of cellular protein than control cultures [F(l, 248)=137.22, p<0.000l]. However, none of 
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Fig 1. Effect of B25-35, EL-lB, TNF-a and EFN-y on astrocyte protein. Astrocytes exposed to 
B25-35 for 8 days had significantly higher content of cellular protein than control 
cultures. However, none of the cytokines tested affected the cellular protein 
content. Values represent mean ± S.E.M. 
None of the cytokines induced an increase in nitrite levels (nmol/mg protein) in 
astrocytic cultures by themselves. However, EFN-y combined with EL-IB or TNF-a induced a 
significant increase in nitrite levels [F(4,203)=75.26, p<0.000l] (Fig. 2). Although both 
EL-IB and TNF-a were effective costimulatory factors, the combination of IFN-y and EL-IB 
was more effective in increasing nitrite levels in cultures than the combination of IFN-y and 
TNF-a (p<0.01). B25-35 sigm'ficantly affected cytokine-mediated increase in nitrite levels 
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Fig 2. Effect of B25-35 on cytokine-mediated astrocytic release of nitric oxide. Astrocytes 
were cultured on B25-35 peptide for 6 days, then exposed to cytokines for 2 days 
before measuring nitrite. None of the cytokines induced an increase in nitrite 
levels (nmol/mg protein) in astrocytic cultures by themselves. However, EETsT-y 
combined with BL-IB or TNF-a induced a significant increase in nitrite levels. 
B25-35 completely blocked the increase in nitrite levels by IFN-y and TNF-a, 
whereas B25-35 only partially blocked the effect of EFN-y and IL-IB. Values 
represent mean ± S.E.M. 
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whereas B25-35 only partially decreased the effect of IFN-y and EL-IB (p<0.01). Thus, nitrite 
levels detected in these cultures were still greater than the levels found in the control 
(p<0.01). This differential effect of B-amyloid on cytokine-mediated release of nitric oxide 
was evidenced by the presence of a significant interaction between B-amyloid. and cytokine 
related effects [F(4,203)=3.35, p<0.01]. 
To examine whether nitrite accumulation in the media was nitric oxide 
synthase-specific, astrocytes were exposed to N°-monomethyl-L-arginine (NMMA: 500 nM). 
The effect of cytokines (IFN-y + EL-lB, IFK-y + TNF-a) on nitrite levels in the astrocytic 
supernatant was substantially reduced by the inclusion of NMMA in the culture, and no 
significant effects of B25-35 or cytokines were detected (Fig. 3). The result indicates that the 
previously described B25-35 and cytokine effects were indeed due to a change in nitric oxide 
synthase activity and the release of nitric oxide, not some other source of nitrite. 
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Fig 3. Effect of N*^-Monomethyl-L-Argimne (NMMA) on astrocytic release of nitric oxide. 
The effect of cytokines (IFN-y+IL-lB, IFN-Y+TNF-a) on nitrite levels in the 
astrocytic supernatant was substantially reduced by the inclusion of NMMA, 
suggesting that the effect of S25-35 and cytokine shown in Fig. 2 was due to a 
change in nitric oxide synthase activity. Values represent mean ± S.E.M. 
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3,2. Effect of Control Peptide On Astrocytic Release Of Nitric Oxide Mediated By IL-lJi, 
TNF-a And IFN-y 
Since our initial experiment did not include scrambled peptide as the control, a 
separate experiment was performed to assess the effect of scrambled peptide on astrocytic 
release of nitric oxide mediated by EL-16, TNF-a and IFN-y. Atrocytes cultured for 6 days on 
scrambled peptide were exposed to each cytokine and their combinations for 2 days after 
which, media were collected and assayed for nitrite content No significant effects of 
scrambled control peptide or cytokines on cellular protein content were detected (data not 
shown). As in the preceding experiment, IFN-y in combination with DL-lB or in combination 
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Fig 4. Effect of control peptide on astrocytic release of nitric oxide. Since our initial 
experiment (Figs. 1, 2) did not include scrambeled peptide as the control, a 
separate experiment was performed to assess the effect of control peptide on 
astrocytic release of nitric oxide. EFN-y in combination with IL-IB or in 
combination with TNF-a were effective in increasing nitrite levels. However, 
scrambled B25-35 peptide did not affect nitrite levels neither alone nor in 
combination with cytokines. Values represent mean ± S.E.M. 
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However, scrambled control peptide did not affect nitrite levels either alone or in 
combination with cytokines. Furthermore, no significant interaction was detected, 
demonstrating specificity of B25-35 peptide effect in the modulation of the nitric oxide 
release fi^om astrocytes. 
4. Discussion 
Previous studies have shown that astrocytes are capable of releasing nitric oxide and 
that certain cytokines including IFN-y, EL-16, and TNF-a are inducers of inducible nitric 
oxide synthase (iNOS) in astrocytes (Murphy et al., 1993). Our present study demonstrated 
that IFN-y (lOOU/ml) in combination with IL-IB (lOOU/ml) or TNF-a (lOOU/ml)) is a potent 
inducer of astroglial release of nitric oxide. Furthermore, we found that EL-IB is a more 
potent cofactor in inducing nitric oxide release from hippocampal astrocytes than TNF-a. 
Since IFN-y, IL-IB, TNF-a and the combination of IL-IB and TNF-a (results not shown) 
failed to induce nitric oxide release, the synergistic action of IFN-y appears to be necessary 
for astroglial release of nitric oxide. Unlike other studies that showed TNF-a alone as an 
iNOS inducer on C6 glioma cells (Murphy et al., 1993; Rossi and Bianchini, 1996), TNF-a 
alone in our study did not enhance the release of nitric oxide from hippocampal astrocytes. 
Similarly, hippocampal microglial cells were also reported not to respond to TNF-a alone 
(Goodwin et al., 1995). 
B25-35 did not alter the astrocytic release of nitric oxide in the presence of cytokines 
IFN-y, TNF-a, or DL-IB. However, it significantly reduced the release of nitric oxide 
mediated by EFN-y in combination with EL-IB or TNF-a. In contrast, a recent report has 
shown that B-amyloid stimulates the production of nitric oxide from C6 glioma cells in the 
presence of cytokines DFN-y, TNF-o, or IL-IB (Rossi and Bianchini, 1996). It is possible that 
this difference in the effect of B25-35 reflects the method used in each study. Our study was 
based on astrocytes from postnatal (P2-5) rat hippocampus and exposing the cultured 
astrocytes to 625-35 for 8 days. This method differs from the previous study (Rossi and 
Bianchini, 1996) in which C6 glioma cells were used in. a shorter exposure time (24 hrs) to 
an aqueous solution, of B25-35. Since the importance of chronic exposure has been shown in 
inducing significant neuronal responses, e.g., apoptosis (Forloni et al., 1993) and oxidative 
stress (Cafe et aL, 1996), our present study was designed to examine a longer-term (8 days) 
effect of B-amyloid on astrocytic release of nitric oxide. 
The other factor considered in the present study was the effect of B-amyloid on cell 
population. In the previous study by Rossi and Bianchini (1996), the nitrite level in C6 cell 
culture was expressed as nitrite per cell population at the time of cell plating in cultures 
exposed to B-amyloid for 24 hrs. B-amyloid is known to induce significant astrocytic 
proliferation within 24 hours (Araujo and Cotman, 1992). Our study also showed a 
significant increase in the total cellular protein by B25-35, suggesting proliferation of 
astrocytes. This effect was specific for B-amyloid as scrambled peptide did not induce a 
similar effect. To account for changes in plated cell population, nitrite levels in the present 
study were expressed as nitrite (rmiol) per milligram of cellular protein, and the percent 
change of nitrite levels from the control cultures was analyzed statistically. Thus, the effect 
of B-amyloid on cytokine-mediated astrocytic release of nitric oxide was not due to astrocytic 
proliferation, but rather to a specific response of each astrocyte. 
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The inhibitory effect of B25-35 on cytokine-mediated release of astrocytic nitric 
oxide was significant, but not equally effective for all cytokines: the inhibitory effect of 
B25-35 on the release induced by IFN-y in combination with TNF-a was complete, while that 
on EFN-y in combination with EL-IB was not. The reason for this difference is not known. 
As shown in the rat astrocyte cell line C6 (Rossi and Bianchim", 1996), IL-IB could be a more 
potent inducer of astrocytic nitric oxide than TNF-a. However, BL-IB alone is known to 
induce nitric oxide release from C6 astrocytes, but not fi-om hippocampal astrocytes (Murphy 
et al., 1993; Simmons and Murphy, 1993). Similarly, hippocampal astrocytes in our present 
study did not respond to EL-16 alone. Since, cultured astrocytes respond to B-amyloid by 
releasing IL-IB (Araujo et al., 1992), it is likely that this additional EL-l may account for the 
incomplete suppressive action of B-amyloid on astrocytic release nitric oxide. 
At present, the importance of astrocyte-derived nitric oxide in the CNS 
pathophysiology is not well understood. Neuronal nitric oxide has been shown to mediate 
glutamate-induced dilation of cerebral arterioles (Faraci and Breese, 1993; Faraci and Brian, 
1994), and inhibitors of nitric oxide synthase block increases in blood flow in neuronaly 
active regions of the brain (Arisztid et al., 1992). These observations support the notion that 
nitric oxide activation of soluble guanyl cyclase in vascular smooth muscle or pericytes may 
modulate cerebral blood flow (Murphy et al., 1993). Similarly, increased astroglial release 
of nitric oxide by cytokines has been proposed to transduce metabolic or intrinsic neuronal 
signaling, and to dilate cerebral vessels and alter cerebral blood flow (Kovach et al., 1992; 
ladecola, 1992; Murphy et al., 1993; Wang et al, 1992). If both neuronal and astrocytic 
nitric oxide play a role in regulating local blood flow, neuronal losses reported in certain 
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areas of the AD brain (Coleman and Flood, 1987) imply that cerebral vasculature may have 
to rely on astrocytes for regulation of the local cerebral blood flow. 
It is conceivable that suppressive action of B-amyloid on astrocytic release of nitric 
oxide may interfere with regxilation of regional cerebral blood flow and could be responsible 
for the reduction in regional cerebral blood flow known to occur in AD patients (Bonte et al., 
1990; Bonte et aL, 1993; Holman et al., 1992). Human astrocytes release nitric oxide upon 
stimulation with a combination of DL-IB and EFN-y (Lee et al., 1993), and increased levels of 
cytokines ( EL-l, TNF-a, EFN-y) have been detected in the brain of AD patients (Dickson et 
al., 1993; Griffin et al., 1989; Haga et al., 1989; Huberman et al., 1994). Therefore, it is 
possible that B-amyloid also exerts a similar suppressive effect on human astrocytes. 
However, it remains to be determined how the modulatory action of B-amyloid on 
astrocyte-generated nitric oxide induced by cytokines may affect vascular ftinctions and local 
cerebral blood flow in situ. 
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Abstract 
B-amyloid is the primary protein component of neuritic plaques, which are 
degenerative foci in brains of patients with Alzheimer's disease (AD). The effects of this 
naturally occurring B-amyloid on the cells of the central nervous system have not been 
completely understood. B-amyloid increases the vulnerability of cultured neurons to 
glutamate-induced excitotoxic damage. Because astrocytes play a key role in uptake of 
extracellular glutamate and glutamate uptake is ATP dependent, we studied the effect of 
B25-35 on glutamate and glucose uptake in cultured hippocampal astrocytes following 7 days 
of exposure to B25-35. Astrocytic glutamate uptake was studied at I, 5, 10, 15, 20, and 60 
min following the addition of [^HJglutamate (5 nM) to the culture media. 
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and astrocytic glucose uptake was assessed at 60 min after the addition of [^""Clglucose (600 
nM and 640 nM) to the media. Glutamate uptake by control astrocytes was time-dependent. 
Astrocytes exposed to G25-35, however, showed significantly lower glutamate uptake at all 
sampling times. Similarly, [^"'CJglucose uptake by astrocj^es was inhibited by 625-35. When 
glucose uptake was blocked by phloretin (10 mM), astrocytic pH]glutamate uptake was also 
blocked, suggesting that the inhibitory effect of B-amyloid on glutamate uptake is caused by 
dimim'shed glucose uptake. Thus, our present study suggests a possible link between two 
proposed mechanisms of pathogenesis of the Alzheimer's disease: glutamate neurotoxicity 
and global defect in cerebral energy metabolism. 
1. Introduction 
6-amyloid is the primary protein component of neuritic plaques, which are 
degenerative foci in brains of patients with Alzheimer's disease (AD) (Marotta et al., 1992). 
The morphology of neuritic plaques varies from diffuse deposits of B-amyloid to dense core 
B-amyloid plaques that usually are associated with dystrophic neurites, reactive astrocytes, 
and microglial cells (Hardy and Allsop, 1991, Ikeda et al., 1990). These observations suggest 
that neuritic plaques progress from a diffuse inert form to B-pleated amyloid plaques 
accompanied by dystrophic neurites. To date, the effects of this naturally occurring 
B-amyloid on cells of the central nervous system have not been determined; however, when 
B-amyloid plaque cores, isolated from brain tissue of AD patients, were injected into the 
hippocampus of rats, neuronal loss was observed by one month post-injection (Frautschy et 
al., 1991). Although the injected material contained all of the constituents of plaques, not just 
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B-amyloid, it is suggestive that B-amyloid from brains of AD patients has neurotoxic 
properties. 
The evidence supporting B-amyloid deposition as the primary pathological process is 
the identification of pathogenic mutations in the B-amyloid precursor protein gene and 
neuropathology similar to AD in transgenic mice overexpressing B-amyloid precursor 
proteins (Games et al, 1995). Although degenerating neurons in transgenic mice accompany 
the B-amyloid deposition, the mecham'sms involved in B-amyloid-mediated neuronal 
degeneration are not v/ell understood. However, it is known that the neurotoxic portion of 
B-amyloid is amino acids 25-35 (B25-35) of the full-length B-amyloid peptide (Bl-43) 
(Mattson et al., 1992, Yanker et al., 1989), and toxicity of B-amyloid depends at least in part, 
on its aggregation states (Pike et al., 1991, Pike et al., 1993). En vitro studies have shown that 
B-amyloid increases the vulnerability of cultured neurons to glutamate-induced excitotoxic 
damage (Kanai et al., 1993) by increasing the influx of extracellular Ca*" and subsequently 
elevating the intraneuronal free Ca** concentration (Joseph and HAn, 1992, Mattson et al., 
1992). These in vitro studies suggest that any condition that elevates focal glutamate levels 
could enhance neuronal susceptibility to excitotoxic cell injury. 
Normally, the extracellular levels of glutamate rise to high levels only briefly and in a 
spatially localized manner during synaptic transmission (Choi, 1988, Nichols and AttwelL, 
1990). Extracellular glutamate is taken up rapidly by astrocytes, where it is converted chiefly 
to glutamine by glutamine synthetase (Farinelli and Nicklas, 1992). The essential role of 
astrocytes in maintaining low extracellular levels of glutamate was demonstrated clearly in 
studies showing a significant increase in neuronal susceptibility to glutamate toxicity' under 
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neuron-astrocyte co-culture with relatively few astrocytes (Rosenberg and Aizenman, 1989). 
Neuronal death, however, occurs even in astrocyte-rich co-culture when glutamate uptake 
into astrocytes is blocked, suggesting the importance of astrocytic glutamate uptake in 
glutamate neurotoxicity (Rosenberg et al., 1992). These findings are important in view of the 
evidence that showed an acute inhibitory effect of 6-amyloid on glutamate uptake into 
cultured astrocytes (Harris et al., 1995; Harris et al., 1996; Parpura-Gill et al., 1995) and that 
glutamate uptake decreases in the brains of AD patients (Kanai et al., 1993). 
Astrocytes require ATP to maintain the glutamate uptake process (Nichols and 
Attwell, 1990; Ogata et al., 1992; Swanson, 1992). As long as glucose is available, astrocytes 
can maintain ATP levels and continue glutamate uptake in both in vitro and in situ 
conditions (Swanson, 1992; Swanson et al., 1994). The presence of glutamate-coupled 
glucose utilization in astrocytes (Pellerin and Magistretti, 1994; Swanson et al., 1990) further 
suggests the interdependency of glucose and glutamate metabolisms in astrocytes. Therefore, 
the purpose of the present study was to explore the effect of B-amyloid on astrocytic 
glutamate and glucose uptakes in vitro. 
2. Materials and methods 
2.1. Synthesis of P-amyloid and scrambled peptide 
B-amyloid (B25-35) and scrambled peptide (Mattson et al.,1992) were synthesized 
and purified by the University of Iowa Protein Facilities (Iowa City, lA). The scrambled 
peptide has the following sequence: H-Ile-Met-Leu-Gly-Asn-Gly-Ala-Ser-Ue-Gly-OH. B25-35 
and the scrambled peptide were dissolved in sterile tissue culture water (Sigma) in a stock 
concentration of 1 mg/ml (pH 7.2). Aliquots were stored at -20°C. Culture wells were coated 
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with B25-35 or scrambled peptide by placing a drop of peptide solution (50 ^.1 of stock 
solution) on to the culture wells. Culture wells were left to dry over night at room 
temperature. 
2.2. Astrocyte cultures 
Astrocytes were obtained from the primary gh'al cultures prepared from the 
hippocampi of P2-5 Sprague-Dawley rats. The hippocampi were dissected and mixed glial 
cultures were grown in flasks containing Eagle's minimum essential medium (MEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 40 mM glucose, 2 mM 
L-glutamine, 1 mM pyruvate, 14 mM sodium bicarbonate, pemcillin (100 i.u./ml), and 
streptomycin 100 |ig/ml (pH 7.35). At confluency, flasks were shaken manually and the 
medium containing non-adherent microglial cells was removed. Fresh medium containing 
additional 5 mM L-leucine-methylester was added to flasks with adherent cells, and the 
flasks were shaken overnight (200 rpm @ 37°C). Then, the medium was removed, and 
adherent cells were scraped from flasks and then mechanically dissociated from each other. 
Cell suspensions were plated into new flasks for 30 min to allow any remaining microglia to 
attach. Non-adherent cells were collected and plated onto 24-well tissue culture plates 
coated with either B25-35 or scrambled control peptide, or directly onto culture wells. More 
than 98% of the cells stained positive for GFAP. 
2.3. Glutamate uptake 
The effect of B-amyloid on glutamate uptake into cultured astrocytes was measured 
by use of L-[G-^H]glutamate (46 Ci/mmol, Amersham). Astrocytes plated directly onto 
culture wells served as the control. At 7 days postplating, the complete culture media were 
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replaced with MEM supplemented with. 10 mM HEPES buffer, and pH]glutamate was added 
to the cultures at 5nM final concentration. To determine background glutamate uptake for 
each experimental group, some cultures were incubated with the glutamate uptake blocker, 
DJL-threo-B-hydroxsyaspartate (TBA; 1 mM), starting 15 min before the addition of 
pH]glutamate to the culture media. Glutamate uptake was stopped at I, 5, 10, 15, 20, and 60 
min by three washes with ice-cold PBS (0. IM Na2HP04,0. IM NaH2P04), and cells were 
lysed in 400 ^l of O.IN NaOH overnight. Cell lysates were used for determination of 
radioactivity by using a beta liquid scintillation counter (Packard, 1600TR) and for assaying 
of total cell protein (Bio-Rad protein assay kit). Glutamate uptake was expressed as pmoles 
of glutamate/mg of total cellular protein. Glutamate uptake is defined as the amount of 
radioactivity derived fi-om pH]glutamate retained in cells at specified times. The experiment 
was performed in triplicate and repeated through at least 3 different culture sessions. 
A separate experiment was performed to assess the effect of scrambled peptide on 
glutamate uptake by comparing uptake by astrocytes plated directly onto culture wells and by 
those plated onto scrambled peptide. In this experiment, [^Hjglutamate uptake in astrocytes 
also was quantified at 1, 5, 10, 15,20, and 60 min following the addition of pH] glutamate 
(46 Ci/mmol) to culture media at a final concentration of 5nM. Cultures treated with 1 mM 
TBA were used to determine background glutamate uptake. Glutamate uptake and total cell 
proteins were assayed in triplicate and were replicated at least 4 times. Glutamate uptake was 
expressed as pmol of glutamate/mg of cellular protein. 
The effect of nitric oxide on glutamate uptake by astrocytes was studied by exposing 
cultured astrocytes to sodium nitroprusside (SNP), which is a spontaneous generator of nitric 
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oxide in aqueous solution (Southam et al., 1991). Sodium nitroprusside (5 mM) was added to 
cultures 15 min before the addition of pHJglutamate at a final concentration of 5nM. 
Glutamate uptake was measured at 5 and 15 min incubation times. Cultures treated with 1 
mM TBA were i^ed to determine background glutamate uptake. Glutamate uptake and total 
cell protein were assayed as described before in triplicate and were replicated at least 4 
times. Glutamate uptake was expressed as pmol of glutamate/mg of cellular protein. 
2.4. Glucose uptake 
Glucose uptake by astrocytes was assessed in cultured astrocytes treated with B25-35 
peptide or scrambled control peptide. Astrocyte cultures treated with glucose uptake blocker, 
phloretin, were used as a positive control in each experiment, and those astrocytes plated 
directly onto culture wells were used as the negative control. At 7 days postplating, culture 
media were replaced with MEM supplemented with 10 mM HEPES buffer, and 
D-[U-'"'C]glucose (313 and 336 mCi/mmol, ICN) was added to the culture wells at final 
media concentrations of 600 nM and 640 nM (0.1 ^Ci/500|.il media in well). The positive 
control cultures received 10 mM phloretin 15 min before addition of ['"'CJglucose. Glucose 
uptake was stopped after 0 and 60 min of incubation by 3 washes v^ath ice-cold PBS. Cells 
were lysed in 400 ^1 of 0. IN NaOH overnight. Cell lysates were used for determination of 
radioactivity and total cell protein. Time 0 was used to determine the background uptake of 
["CJglucose. Glucose uptake was expressed as nmol of glucose/mg of cellular protein. 
Glucose uptake is defined as the amount of radioactivity derived fi:om [''•CJglucose retained 
in cells at specified times. All experiments were conducted in triplicate and repeated in at 
least 4 separate cultures. 
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2.5. Inhibitory effect of phloretin on glutamate uptake 
The role of glucose on glutamate uptake was studied by exposing cultures to 10 mM 
phloretin. At 7 days postplating, culture media were replaced with MEM supplemented with 
10 mM HEPES buffer, and pH] glutamate (46 Ci/mmol) was added to culture wells at a final 
concentration of 5nM. Phloretin was added 15 min before addition of pH] glutamate. 
Glutamate uptake was stopped at 0 and 60 min incubation periods by 3 washes with 
ice-cold PBS. Cultures treated with I mM TBA were used to determine background 
glutamate uptake. Glutamate uptake and total cell protein were assayed in triplicate and were 
replicated at least 3 times. Glutamate uptake was expressed as pmol of glutamate/mg of 
cellular protein. 
2.6. Total cell protein assay 
Total cell protein in each culture well was determined by using the Bio-Rad Protein 
Assay kit. Protein concentrations v/ere calculated from the absorbency values. The standard 
curve was obtained by using bovine gamma globulin as a standard at serial dilutions in the 
linear range of the assay. Absorptions were read on an Elisa reader at 595 nm (Molecular 
Devices). 
2.7 Statistical analysis 
All data were analyzed for treatment differences by using analysis of variance 





3.1. Effect of fi25-35 on astrocytic glutamate uptake 
To examine whether 6-amyloid has a time-dependent effect on glutamate uptake into 
cultured astrocytes, glutamate uptake was studied at I, 5, 10, 15, 20, and 60 min following 
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Fig. I. Effect of B25-35 on astrocytic glutamate uptake. Astrocytes were exposed to B25-35 
peptide for 7 days after plating on day 0. The accumulation of pH]glutamate in 
the control astrocytes was significantly greater than that in those groups exposed 
to B25-35 at all assay times [P<0.0001]. This greater level of glutamate uptake in 
control astrocytes also increased linearly with time (rM).87). As indicated by the 
absence of interaction between the sampling time and the experimental condition 
(control and B-amyloid-treated), results indicate the inhibitory action of 




Astrocytes plated directly onto culture wells served as the control. The accumulation of 
pH]glutamate in the control astrocytes was sigm"ficantly greater than that in those groups 
exposed to B25-35 at all assay times [F(l,143)=54.29, P<0.0001]. This greater level of 
glutamate uptake in control astrocytes also increased linearly with time (rM).87). In contrast, 
astrocytes exposed to B25-35 showed significantly lower glutamate uptake as compared with 
that of control astrocytes at all sampling times [F(l, 143)=54.29, P<0.0001]. As indicated by 
the absence of interaction between the sampling time and the experimental condition 
(control and B-amyloid-treated), the results clearly indicate the inhibitory action of B-amyloid 
on glutamate uptake by astrocytes. 
Since our initial experiment did not include scrambled peptide as the control, a 
separate experiment was performed to assess the effect of scrambled peptide on glutamate 
uptake. Glutamate uptake by astrocytes was studied in the same manner as in the previous 
experiment. There was no difference in glutamate uptake between astrocytes plated directly 
onto culture wells and those plated onto the scrambled control peptide (data not shown). 
Both groups of astrocytes showed a time-dependent linear increase in glutamate uptake 
(rM).87). These results suggest that glutamate uptake is not affected by the scrambled 
control peptide, but is inhibited by B25-35. 
3.2. Effect of P25-35 and nitric oxide on astrocytic glutamate uptake 
Sodium nitroprusside (SNP) was used to study the effect of nitric oxide on astrocytic 
glutamate uptake at 5 and 15 min following exposure to pH]glutamate (Fig. 2). Sodium 
nitroprusside (0.5 mM) did not affect glutamate uptake into astrocytes as the uptake by 
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Fig. 2. Effect of 625-35 and nitric oxide on astrocytic glutamate uptake. Astrocytes were 
exposed to 625-35 peptide for 7 days after plating on day 0. At 7 days 
postplating, the effect of sodium nitroprusside (SNP) on glutamate uptake was 
measured at 5 and 15 min incubation times. SNP (0.5 mM) did not affect 
astrocytic glutamate uptake. Accumulation of glutamate in control astrocytes was 
significantly higher at 15 min sampling time than at 5 min [P=0.00l]. However, 
astrocytes exposed to 625-35 showed significantly lower glutamate levels than the 
control astrocytes did at both sampling times [P=0.0016]. A combination of SNP 
and 625-35 did not induce any more significant inhibition than 625-35 alone did 
at either 5 or 15 min sampling times, confirming that SNP does not inhibit 
glutamate uptake into astrocytes. Values represent mean ± S.E.M. (n=l2). 
However, astrocytes exposed to 625-35 showed significantly lower glutamate uptake than the 
control astrocytes did at both sampling times [F(l,88)=10.65, P=0.0016]. A combination of 
SNP and 625-35 did not cause any more significant inhibition than 625-35 alone did at either 
5 or 15 min sampling times, confirming that SNP does not inhibit glutamate uptake into 
astrocytes. 
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3.3. Effect of /I25-35 on astrocytic glucose uptake 
To assess astrocytic glucose uptake, astrocytes treated with B25-35 or scrambled 
control peptide were incubated with ["CJglucose for 60 min. Phloretin-treated clotures were 
used as a positive control in each experiment and those astrocytes plated directly onto culture 
wells were used as the negative control. Glucose uptake was significantly lower in the 
astrocytes exposed to B25-35 (P<0.01) or phloretin (P<0.01) as compared with that of the 
control groups [F(3,47)=6.189, P=0.0013] (Fig. 3). 
Fig. 3. Effect of B25-35 on astrocytic glucose uptake was assessed by exposing astrocytes to 
B25-35 or scrambled control peptide for 7 days, followed by incubating them with 
['•'Clglucose for 60 rain. Phloretin-treated cultures (15 min prior to addition of 
['•*C]glucose) were used as a positive control in each experiment, and those 
astrocytes plated directly onto culture wells were used as the negative control. 
Glucose uptake was significantly affected by treatments [P=0.0013]. The groups 
of astrocytes exposed to B25-35 (P<0.01) or phloretin (P<0.01) showed 
significantly lower glucose uptake as compared with the control groups. Values 
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Astrocytes plated onto scrambled control peptide did not differ in glucose uptake from those 
plated directly onto culture wells, suggesting a specific inhibitory action of B25-35 on 
glucose uptake by astrocytes. 
3.4. Effect of phloretin on glutamate uptake into astrocytes 
To test the hypothesis that glutamate uptake into astrocytes is dependent upon 
glucose uptake, glutamate uptake into astrocytes was assessed following exposure to 
phloretin, a glucose uptake blocker. Astrocytes exposed to phloretin absorbed significantly 
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Fig. 4. Effect of phloretin on glutamate uptake into astrocytes. At 7 days post-plating, 
pH]glutamate uptake into astrocytes was assessed following 15 min exposure to 
10 mM phloretin, a glucose uptake blocker. Astrocytes exposed to phloretin were 
found to take up significantly less glutamate than these in the control culture 
[P=0.0017]. Values represent mean ± S.E.M. (n=9). 
4. Discussion 
In our present study, giutamate and glucose uptakes were examined in cultured 
astrocytes following 7 days of exposure to B25-35. The cellular effects of B-amyloid were 
studied by using a synthetic 6-amyloid peptide (B25-35) that corresponds to amino acids 
25-35 of the ftill length peptide. Astrocytes were exposed to B25-35 coated onto the surface 
of culture wells (Goodwin et aL, 1995). This exposure method differs from that of previous 
studies that have sought to determine the effects of 6-amyloid by solubilizing it or 
suspending it in culture medium despite the fact that the B-amyloid found in the AD neuritic 
plaques is immobile and insoluble. Coating B25-35 onto wells of a culture dish not only 
ensures that most cells are exposed to B25-35, but it also prevents any possible physical cell 
damage by aggregated, mobile B25-35 in culture medium. 
The present study on giutamate uptake into astrocytes supports the previous studies 
(Harris et al., 1995; Harris et al., 1996; Parpura-Gill et aL, 1995). Our initial study 
demonstrated that 625-35 inhibits giutamate uptake by cultured hippocampal astrocytes 
(Parpura-Gill et al., 1995). To further investigate the inhibitory effects of B-amyloid on 
giutamate uptake by astrocytes, the present study examined giutamate uptake by using 
postnatal (P2-5) rat hippocampus and exposing the cultured astrocytes to 625-35 for 7 days. 
This method differs from previous studies by Harris et al. (1995, 1996) in which fetal (El8) 
astrocyte cultures were used in a short exposure time (30 min) to an aqueous solution of 
B25-35. The importance of chromc exposure in inducing significant neuronal responses, e.g., 
apoptosis (Forloni et al., 1993) and oxidative stress (Cafe et al., 1996) has been shown. 
Therefore, our present study was to examine the long-term (7 days) effect of B-amyloid on 
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astrocytic glutamate and glucose uptake in vitro. Glutamate uptake by control astrocytes was 
shown to be time-dependent, as had been reported previously (Flott and Seifert, 1991; Hara 
et aL, 1989; Piam' et aL, 1993). However, those astrocytes plated onto B25-35 for 7 days 
showed significantly lower glutamate uptakes regardless of the sampling times (1 min to 1 
hr). This inhibitory effect is specific to B25-35, because the scrambled control peptide did 
not affect the astrocytic glutamate uptake. 
The inhibitory effect of B-amyloid on glutamate uptake by astrocytes suggests the 
possibility of increased neuronal vulnerability in the brain of AD patients. Both neurons and 
astrocytes possess a high affinity glutamate uptake system (Kanai et al., 1993); however, 
astrocytes have been demonstrated to take up most of the extracellular glutamate 
(McLennan, 1976). Since glutamine synthetase is found in astrocytes (Norenberg and 
Martinez-Hernandez, 1979), glutamate in culture media should be taken up rapidly by 
astrocytes, where it is converted chiefly to glutamine by the glutamine synthetase (Farinelli 
and Nicklas, 1992). Therefore, the decreased capacity of astrocytes to uptake glutamate may 
have significant effects on neuronal function and survival. 
Glutamate-mediated neuronal cell injury has been studied extensively (Choi, 1988, 
Meldrum and Garthwaite, 1990). An excessive Ca-* influx through NNDDA glutamate 
receptors and prolonged elevations in intracellular Ca^" levels lead to cell death (Meldrum 
and Garthwaite, 1990; Siesjo, 1989). This Ca-* influx mediated by glutamate activates 
Ca^*-dependent nitric oxide synthase in cultured cortical neurons, and this process can be 
prevented by nitric oxide synthase inhibitor (Vige et al., 1993) or competitively reversed by 
L-arginine (Dawson et al., 1991). Nitric oxide at high levels is neurotoxic (Chao et al., 1992). 
It reacts with superoxide anions and forms peroxinitrite anions that decompose to yield 
highly damaging hydroxyl free radicals and nitrogen dioxide (Beckman et al., 1990). 
Furthermore, nitric oxide inhibits glutamate transport in hippocampal synaptosomes from rat 
brain (Pogun et al., 1994). These observations suggest nitric oxide as one mediator of the 
glutamate neurotoxicity. However, when SNP was used as a nitric oxide generator (Southam 
and Garthwaite, 1991), we did not detect any effect of nitric oxide on glutamate uptake by 
astrocytes. Neuronal and glial glutamate carriers are structurally different and respond 
differently to glutamate uptake blocker (Kanai et al., 1993). Therefore, it is likely that SNP 
affects glutamate uptake differendy in astrocytes and synaptosomes. 
The mechanism involved in B-amyloid-mediated inhibition of glutamate uptake is not 
known. B-amyloid generates oxygen-dependent free radicals in aqueous solution (Hensley et 
al., 1994), and it was suggested that these oxygen-dependent free radicals are responsible for 
inhibition of glutamate uptake into astrocytes (Harris et al., 1995; Harris et al., 1996). 
Moreover, the scrambled control peptide also was shown to induce significant levels of free 
radicals in aqueous solution (Hensley et al., 1994). Because our present study and that of 
Harris et al. (1996) showed that scrambled B25-35 has no inhibitory effect on astrocytic 
glutamate uptake, it is possible that B-amyloid may interfere with astrocytic glutamate uptake 
by some free radical-independent mechanisms. 
In light of evidence showing that glutamate uptake is dependent mainly on glucose 
availability rather than oxygen (Swanson, 1992; Swanson et al., 1994) and that inhibition of 
glycolysis causes failure of glutamate uptake (Ogata et al., 1992; Swanson, 1992), we studied 
the effect of B25-35 on glucose uptake by astrocytes. The B25-35 exerted significant 
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inhibition on astrocytic glucose uptake, suggesting that the suppressive effect of B-amyloid 
on astrocytic glucose uptake affects glutamate uptake. To fixrther support our hypothesis, we 
studied astrocytic glutamate uptake in the presence of phloretin, a glucose uptake blocker. 
Pholoretin induced approximately a fourfold decrease in glutamate uptake, which is 
comparable to the fourfold decrease in the glutamate uptake (measured at 60 min sampling 
time) by 625-35. Our finding that phloretin also inhibits glutamate uptake may explain the 
previous studies that demonstrated glucose dependency of glutamate uptake in situ 
(Swanson et al., 1994). Since glial cells may respond differently to 625-35 and 31^0 
(Goodwin et al., 1995), confirmation of the present study using full length 6-amyloid peptide 
needs to be done in future studies. 
Ample evidence has been provided to show that glucose metabolism may have 
changed in the brains of AD patients (Hoyer, 1991). Studies by positron emission 
tomography (PET) scans detected a decrease in glucose uptake and metabolism in the 
cerebral cortex (Duara et al., 1986; Jagus et al., 1991; Rapoport et al., 1991; Riege et al., 
1988) and immunohistochemistry revealed a decrease in GLUTl and GLUT3 activities in 
several regions of the brain including the hippocampus (Harr et al., 1995; Simpson et al., 
1994). These studies suggested that the decrease in cerebral glucose uptake seen in PET 
studies may reflect, in part, decreased glucose transport and utilization at the cellular level. 
This change in glucose metabolism may result in the lower glutamate uptake found in the 
brain of AD patients (Kanai et al., 1993). Although our present study based on cultured rat 
astrocytes may not accurately represent an in situ environment for astrocytes, previous in 
vitro experiments (Araujo and Cotman, 1992) have often proved their usefulness in 
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simulating cellular responses in situ (Gomez-Pinilla et al., 1990; Griffin et al., 1989; Haga et 
al., 1989). Thus, our present data predicts that B-amyloid may cause a decrease in astrocyte 
glucose uptake in the human brain. The hallmark of the Alzheimer's disease is the neuritic 
plaque that consists of a 6-amyloid protein core surrounded by dystrophic neurites and 
reactive astrocytes (Hardy and Allsop, 1991). The functional role played by these reactive 
astrocytes is not known, but it is possible that neuronal degeneration associated with 
B-amyloid plaque is induced in part by reactive astrocytes that failed to maintain normal 
glucose metabolism. We propose that 6-amyloid inhibition of astrocytic glucose uptake 
limits glutamate uptake in the brain of AD patients. This condition potentiates a decrease in 
glucose incorporation into glycogen (Swanson et al., 1990), which could potentially lead to 
glycogen depletion in astrocytes. Since glycogen in the brain is stored primarily in astrocytes, 
the neurotoxic action of B-amyloid may involve limiting the availability of glucose in the 
brain of AD patients by limiting glucose uptake and subsequent depletion of glycogen in 
astrocytes. Thus, our present study suggests the possible link between two proposed 
mechanisms of pathogenesis of the Alzheimer's disease: glutamate neurotoxicity (Choi, 
1988; Meldrum and Garthwaite, 1990) and global defect in cerebral energy metabolism 
(Marcus et al., 1989). 
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GENERAL DISCUSSION 
The present studies suggested the effect of j3-ainyloid on astrocytes in the 
pathogenesis and pathophysiology of AD as related to the astrocytes' functions of; 1) 
regulation of cerebral blood flow by their release of nitric oxide, and 2) regulation of brain 
microenviroment by maintenance of low extracellular levels of glutamate through a 
glutamate uptake process and adequate glucose supply as a main glycogen reserve in the 
brain. 
The Effects of Cytokines on Astrocytic Nitric Oxide Release 
In the first study of this dissertation, the effects of (3-amyloid and cytokines (IFN-y, 
IL-lB, and TNF-a) on nitric oxide release by astrocytes were examined. Previous studies 
have shown that astrocytes are capable of releasing nitric oxide (Simmons and Murphy, 
1992), and that the combination of cytokines (IFN-y and IL-IB) induced iNOS and 
subsequent nitric oxide release by astrocytes (Murphy et al., 1993). The present dissertation 
confirmed the previous finding that exposure of astrocytes to individual cytokines (EL-ip, 
TNF-a and IFN-y) is not sufficient for the induction of the nitric oxide release by astrocytes, 
whereas, EFN-y (lOOU/ml) in combination with EL-IB (lOOU/ml) is a potent inducer of 
astroglial release of nitric oxide. Furthermore, the present study revealed yet another inducer 
of astrocytic nitric oxide release, a combination of cytokines IFN-y and TNF-a. Notably, the 
combination of EL-IB and TNF-a did not cause the induction of astrocytic nitric oxide 
release. The present study also demonstrated that IL-IB is a more potent LFN-y 
costimulatory factor than TNF-a in inducing nitric oxide release from hippocampal 
astrocytes. This finding of obligatory synergistic action of IFN-y with IL-IB, or TNF-a in 
inducing astroglial nitric oxide release is particularly important in light of evidence for the 
temporal relationship between the severity of AD and levels of cytokines (lL-1, IFN- y and 
TNF-a) (Aisen and Davis, 1994; Huberman et al., 1994; Sheng et al., 1997). 
Previous studies have implicated EL-1 as a driving force in the progression of AD 
pathology because it induces amyloid precursor protein mRNA and thus favoring |3-amyloid 
production (Aisen and Davis, 1994; Sheng et al., 1997). It also appears that DL-l is the only 
cytokine reported in the brain during early stages of AD (Griffin et al., 1995). A correlation 
between IFN-y production and the severity of AD was also demonstrated. Increased IFN-y 
production by mononuclear cells was detected in patients with the advanced stage of AD, 
while no change in IFN-y production was detected in mild AD cases (Huberman et al., 1994). 
Additionally, T cells (IFN-y producers) have been co-localized with most of mature neuritic 
plaques (Rogers et al., 1998). 
While other studies have shown that TNF-a alone can induce iNOS in C6 glioma 
cells (Murphy et al., 1993; Rossi and Bianchini, 1996), in the present study TNF-a alone did 
not enhance the release of nitric oxide fi-om hippocampal astrocytes. Similarly, hippocampal 
microglial cells were also reported to be unresponsive to TNF-a alone (Goodwin et al., 
1995). It appears that TNF-a levels in AD patients reflect the disease stage as previously 
noted for IFN-y levels. In mild cases of AD TNF-a production by mononuclear cells was 
decreased (Huberman et al., 1994), but an increased TNF-a serum level was detected in the 
overall AD patient population (Fillit et al., 1991). The relationship between the disease stage 
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and the TNF-a levels is also suggested in the hypothesis stating that changes in TNF-a levels 
in AD result from either local cerebral or systemic inflammatory reaction associated with AD 
(Fillit et al., 1991). Although, EL-1 appears to be the first cytokine detected in the brain 
tissue, during the progression of AD, the present results showed no astrocytic nitric oxide 
release upon stimulation with IL-ip. Therefore, astrocytic nitric oxide release should not 
play a significant role in the pathology of early AD. However, with the fiirther progression 
of AD, an increase in level of IFN-y could act as a costimulatory factor needed for the 
induction of astrocytic nitric oxide release. Additionally, as EFN-y levels increase in latter 
stages of the disease, so do TNF-a levels, and thus another stimulatory combination of 
cytokines could induce nitric oxide release from astrocytes. 
Gradual changes of cytokine production (Androsova et al., 1995; Rogers et al., 1998) 
in AD patients from slight to marked production of IFN-y and TNF-a and the correlation with 
the severity of the disease (Androsova at al.,l995; Shalit et al., 1995) fiirther support the 
temporal dependency of cytokine effects and their role in the pathogenesis of AD. 
B-Amvloid and Nitric Oxide Release 
B25-35 did not stimulate the astrocytic release of nitric oxide alone or in the presence 
of either individual cytokines (IFN-y, TNF-a, or IL-IB) or cytokine combinations (IFN-y and 
TNF-a, or IFN-y and IL-IB). Conversely, |3-amyloid significantly reduced the astrocytic 
release of nitric oxide induced by EFN-y combination with IL-IB or TNF-a. Given the role of 
nitric oxide in regulation of cerebral blood flow (Faraci and Brian, 1994), the present finding 
is important because it implicates P-amyloid as a modulator of cerebrovascular function in 
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AD. To further clarify the importance of the current findings, one needs to review the 
regulation of cerebral blood flow. 
Cerebral circulation is regulated mainly by I) neurotransmitter release from 
perivascular neurons and 2) endothelial factors (Whal and Schilling, 1993). Coupling 
between cerebral flmction and blood flow is one of the fundamental characteristics of 
cerebral circulation and is mostly mediated by nitric oxide (Whal and Schilling, 1993; 
Bruhwyler et al., 1993). Neurotransmitter release (e.g.. Acetylcholine) from perivascular 
neurons causes endothelium dependent vasodilatation as the neurotransmitter activates 
endothelial NOS which, in turn, produces nitric oxide, relaxing the vascular muscle cells. 
Neuronal nitric oxide has been shown to mediate glutamate-induced dilation of cerebral 
arterioles (Farachi and Breese, 1993; Farachi and Brian, 1994) most likely through activation 
of soluble guanyl cyclase in vascular smooth muscle or pericytes. Furthermore, inhibitors of 
nitric oxide synthase block increases in blood flow in neuronally active regions of the brain 
(Arisztid et al., 1992). Cytokines induced astroglial release of nitric oxide has been proposed 
to dilate cerebral vessels and alter cerebral blood flow (Kovach et al., 1992; ladecola, 1992; 
Murphy etal., 1993; Wangetal., 1992). 
It was demonstrated that aging has an inhibitory effect on endothelium-dependent 
cerebral vasodilatation (Faraci and Brian, 1994). Additionally, a recent in vitro study 
revealed that p-amyloid induces necrotic endothelial cell death and inhibits the production of 
nitric oxide (Sutton et al., 1997). Since the neuronal loss is one of the hallmarks of AD and 
vasoactive endothelial function is significantly impaired (Faraci and Brian, 1994; Sutton et 
al., 1997), it may be that the local cerebral blood flow is almost entirely dependent on 
astrocytic regulation. Under these circumstances, P-amyloid mediated inhibition of the 
astrocytic nitric oxide release would have a down regulatory effect on cerebral blood flow in 
AD patients. Indeed, a reduction in cerebral blood flow in AD patients has been already 
reported (Bonte et al., 1990; Bonteetal., 1993; HohnanetaL, 1992). 
Similar to the present study findings based on rat astrocytes cultures, human 
astrocytes release nitric oxide upon stimulation with a combination of IL-IB and EFN-y (Lee 
et al., 1993), and increased levels of cytokines ( IL-l, TNF-o, EFN-y) have been detected in 
the brains of AD patients (Dickson et al., 1993; Griffin et al., 1989; Haga et al., 1989; 
Huberman et al., 1994). It is, therefore, reasonable to assume that B-amyloid exerts a similar 
suppressive effect on human astrocytes' nitric oxide release. The underlying mecham'sm of 
how the modulatory action of B-amyloid on astrocyte-generated nitric oxide induced by 
cytokines may affect vascular functions and local cerebral blood flow in situ is yet to be 
determined. 
The Effect of B-Amvloid on Astrocytic Glutamate Uptake 
The present study examined the long-term (7 days) effect of B-amyloid on astrocytic 
glutamate uptake. Glutamate uptake by control astrocytes (not exposed to amyloid) was 
shown to be time-dependent, as reported previously (Flott and Seifert, 1991; Hara et al., 
1989; Piani et al., 1993). However, astrocytes plated onto B25-35 for 7 days showed 
significantly lower glutamate uptakes regardless of the sampling times (1 min to 1 hr). This 
inhibitory effect is specific to B25-35, because the scrambled control peptide did not affect 
the astrocytic glutamate uptake. The significance of this finding is related to glutamate 
toxicity implicated in AD pathogenesis. Neurotoxic properties of glutamate have been well 
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documented as a cause of neuronal death in AD (Maragos et al., 1987). The inhibitory effect 
of B-amyloid on astrocytic glutamate uptake suggests an accumulation of extracellular 
glutamate and prolonged neuronal exposure to elevated levels of glutamate. 
Glutamate-mediated neuronal cell injury has been studied extensively (Choi, 1988; Meldrum 
and Garthwaite, 1990). An excessive Ca^" influx through NMDA glutamate receptors and 
prolonged elevations in intracellular Car levels lead to cell death (Meldrum and Garthwaite, 
1990; Siesjo, 1989). Glutamate toxicity has been proposed as a pathogenic factor in AD. The 
finding in the present study supports that hypothesis and, in addition offers a possible 
explanation of the mechanism responsible for elevation of glutamate levels. 
Both neurons and astrocytes possess a high affinity glutamate uptake system (Kanai 
et al., 1993) which maintains low extracellular glutamate levels. However, astrocytes appear 
to play a key role in maintenance of low glutamate levels because they take up most of the 
extracellular glutamate (McLennan, 1976). Therefore, the decreased capacity of astrocytes 
to uptake glutamate may have significant effects on neuronal function and survival because 
elevated glutamate levels could induce toxic effects. If one takes into consideration that 
P-amyloid itself increases neuronal susceptibility to glutamate toxicity (Koh et al., 1990), 
P-amyloid inhibition of astrocytic glutamate uptake and subsequent elevation of extracellular 
glutamate may be sufficient to cause neuronal death. The mechanism involved in 
B-amyloid-mediated inhibition of glutamate uptake is not known and some of the possible 
factors (e.g. nitric oxide, glucose) that may affect astrocytic glutamate uptake were 
investigated in this dissertation. 
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Astrocytic Glutamate Uptake and Nitric Oxide 
The possible effect of nitric oxide on astrocytic glutamate uptake was exaniined using 
sodiuin nitropnisside (SNP), a spontaneous nitric oxide generator (Southam and Garthwaite, 
1991). Nitric oxide has been suggested as a mediator of the glutamate neurotoxicity as the 
Ca-" influx mediated by glutamate activates Ca^'-dependent nitric oxide synthase (Vige et 
aL, 1993). At high levels, nitric oxide is neurotoxic (Chao et al., 1992) because it reacts with 
superoxide anions and forms peroxinitrite anions that decompose to yield highly damaging 
hydroxyl free radicals and nitrogen dioxide (Beckman et al., 1990). Furthermore, nitric 
oxide inhibits glutamate transport in hippocampal synaptosomes from rat brain (Pogun et al., 
1994). These observations suggest nitric oxide as a factor that may mediate glutamate 
neurotoxicity. However, the present study showed that SNP did not affect glutamate uptake 
by astrocytes. A combination of SNP and B25-35 did not cause any more significant 
inhibition than that caused by B25-35 alone, confirming that SNP does not affect astrocytic 
glutamate uptake. These results are significant because they are suggestive of two different 
glutamate uptake processes in neurons and astrocytes. 
The finding that astrocitic glutamate uptake is not affected by SNP suggests that 
nitric oxide mediation of glutamate neurotoxicity is not related to changes in astrocytic 
glutamate uptake. Considering that nitric oxide does inhibit glutamate transport in 
hippocampal synaptosomes from the rat brain (Pogun et al., 1994), whereas astrocytic uptake 
is not affected by nitric oxide, it is likely that the glutamate carrier in synaptosomes has a 
different susceptibility to nitric oxide than the astrocytic carrier as demonstrated by an 
opposite effect of SNP on astrocytic and neuronal glutamate uptakes. 
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Astrocytic Giutamate Uptake and Oxygen Dependent Free Radicals 
B-amyloid generates oxygen-dependent free radicals in an aqueous solution (Hensley 
et al., 1994), and it has been suggested that these oxygen-dependent free radicals are 
responsible for the inhibition of giutamate uptake into astrocytes (Harris et al., 1995; Elarris 
et al., 1996). Moreover, the scrambled control peptide was also shown to induce significant 
levels of free radicals in an aqueous solution (Hensley et al., 1994). Since the present study 
also showed that scrambled B25-35 has no inhibitory effect on astrocytic giutamate uptake, it 
is likely that B-amyloid may interfere with astrocytic giutamate uptake by a free 
radical-independent mechanisms (e.g. glucose uptake). 
Astrocytic Glucose Uptake and B-Amyloid as Related to Giutamate Uptake 
This study tested the effect of B25-35 on glucose uptake by astrocytes. It has been 
shown that astrocytic giutamate uptake depends mainly on glucose availability (Swanson, 
1992; Swanson et al., 1994) and that inhibition of glycolysis causes failure of giutamate 
uptake (Ogata et al., 1992; Swanson, 1992). In the present study, B25-35 exerted significant 
inhibition on astrocytic glucose uptake, suggesting that the suppressive effect of B-amyloid 
on astrocytic glucose uptake may affect giutamate uptake. To further support this hypothesis 
, astrocytic giutamate uptake was studied in the presence of phloretin, a glucose uptake 
blocker. Phloretin induced approximately a fourfold decrease in giutamate uptake, which is 
comparable to the fourfold decrease in the giutamate uptake induced by B25-35 (measured at 
60 min sampling time). The demonstrated phloretin effect on astrocytic giutamate uptake 
suggests that the suppressive effect of S25-35 on glucose uptake, in turn, affects giutamate 
uptake. 
Ample evidence has been provided to show that glucose metaboh'sm may have 
changed in the brains of AD patients (Hoyer, 1991). Studies using positron emission 
tomography (PET) scans detected a decrease in glucose uptake and metabolism in the 
cerebral cortex (Duara et al., 1986; Jagus et al., 1991; Rapoport et al., 1991; Riege and 
Metter, 1988), and immunohistochemistry revealed a decrease in GLUTl and GLUT3 
activities in several regions of the brain, including the hippocampus (Harr et al., 1995; 
Simpson et al., 1994). These studies suggest that the decrease in cerebral glucose uptake seen 
in PET studies may reflect, in part, decreased glucose transport and utilization at the cellular 
level. Additionally, it appears that this change in glucose metabolism may result in the lower 
glutamate uptake also found in the brain of AD patients (Kanai et al., 1993). Although the 
present study, based on cultured rat astrocytes, may not accurately represent an in situ 
environment for astrocytes, previous in vitro experiments (Araujo and Cotman, 1992) have 
often proved their usefulness in simulating cellular responses in situ (Gomez-Pinilla et al., 
1990; Griffin et al., 1989; Haga et al., 1989). Thus, the present dissertation findings support 
the hypothesis that B-amyloid may cause a decrease in astrocyte glucose uptake in the human 
brain. 
Concluding Remarks 
The hallmark of Alzheimer's disease is the neuritic plaque that consists of a 
B-amyloid protein core surrounded by dystrophic neurites and reactive astrocytes (Hardy and 
Allsop, 1991). Even though Alziieimer's disease has not been considered an "inflamatory 
disease", evidence in recent years suggests that the degenerative processes in AD are 
accompanied by activation of immune mechanisms (Aisen and Davis, 1994). 
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It has been demonstrated that EL-1 causes the induction of amyloid precursor protein 
mRNA and thus creates an environment favoring |3-amyloid production (Sheng et al., 1996). 
Since p-amyloid deposition is considered a central event in pathogenesis of AD, the effect 
of IL-1 has been proposed as one of the first and perpetuating factors in amyloidogenesis 
and. AD pathogenesis (Aisen and Davis, 1994) (Chart I). Astrocytes proliferate in response 
to DL-IB, and they also release TNF-a (Aisen and Davis, 1994). As IL-I induces 
amyloidogenesis and P-amyloid deposition, astrocytes change their morphology and release 
additional BL-l (Araujo and Cotman, 1992), thus perpetuating a vicious circle. 
With the progression of the pathologic processes in AD, additional cytokines (TNF-a 
and [FN-y) are produced (Huberman et al., 1994; Fillit et al., 1991; Araujo and Cotman, 
1992). As they diffuse into the brain parenchyma, the combinations of these cytokines can 
induce astrocytes to release nitric oxide, which could potentially be neurotoxic in AD brains. 
However, P-amyloid suppresses this effect leading to a decrease in astrocytic nitric oxide 
release as demonstrated in the present study. It is through release of nitric oxide that 
astrocytic endfeet processes mediate dilation of cerebral vasculature (Montgomery, 1994; 
Faraci and Brian, 1994). Therefore, in AD brains, the presence of P-amyloid (e.g., 
perivascular deposits) would lead to impaired vascular dilation resulting in reduced cerebral 
blood flow (Chart 1). 
Additionally, it is also possible that neuronal degeneration associated with B-amyloid 
plaque is induced in part by reactive astrocytes that failed to maintain normal glucose 
metabolism (Chart 1). Besides a reduced glucose supply caused by reduced cerebral blood 
flow, additional B-amyloid inhibition of astrocytic glucose uptal;e would limit glutamate 
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Chart 1: Putative role of astrocytes in pathogenesis of AD 



















uptake in the brain of AD patients. This condition potentiates a decrease in glucose 
incorporation into glycogen (Swanson et al., 1990), which could potentially lead to glycogen 
depletion in astrocytes. Since glycogen in the brain is stored primarily in astrocytes, the 
neurotoxic action of B-amyloid may involve limiting the availability of glucose in the brain 
of AD patients by limiting glucose uptake and subsequent depletion of glycogen in 
astrocytes. Thus, our present study suggests the possible link between two proposed 
mechamsms of pathogenesis of the Alzheimer's disease: glutamate neurotoxicity (Choi, 
1988; Meldrum and Garthwaite, 1990) and global defect in cerebral energy metabolism 
(Marcus et al., 1989). 
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